Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. reported the results of its 2026 annual meeting of stockholders held on July 16, 2026. Proxies representing approximately 45.7% of outstanding common shares constituted a quorum. Stockholders elected six directors to serve until the 2027 annual meeting and ratified the selection of WithumSmith+Brown, PC as independent registered public accounting firm for the year ending December 31, 2026. However, stockholders did not approve, on a non-binding, advisory basis, the compensation of the named executive officers, with 46,024,068 votes for, 51,842,781 against and 2,300,962 abstentions, plus 10,463,289 broker non-votes.
The company also described its focus as a clinical-stage biotechnology company developing oral recombinant pill vaccines, including a Phase 2b trial of its oral COVID-19 vaccine candidate supported in part by Project NextGen and the RRPV Consortium.
Vaxart, Inc. reported 12‑month topline safety data from the approximately 400‑participant sentinel safety cohort in its Phase 2b trial of an oral pill COVID‑19 vaccine versus an approved mRNA comparator. Participants received either Vaxart’s oral pill vaccine (201 people) or an mRNA vaccine (199 people) targeting the XBB strain of SARS‑CoV‑2.
No vaccine‑related serious adverse events or sustained Grade 3 or higher adverse events were observed in either arm over 12 months, supporting a favorable safety profile for both regimens in this cohort. The full study includes this sentinel cohort plus about 5,000 participants in a main cohort dosed with vaccines targeting the KP.2 strain, with complete data anticipated in 2027.
The program is supported by Project NextGen through BARDA, ASPR, HHS and NIAID under a Rapid Response Partnership Vehicle Consortium award valued at up to $344.8 million, helping fund development of Vaxart’s proprietary oral pill vaccine platform.
Vaxart, Inc. and a group of stockholders led by Daniel P. Houle entered a Cooperation Agreement that resolves an active proxy contest and withdraws the stockholders' slate of nominees for the 2026 annual meeting.
Under the agreement the Concerned Vaxart Stockholders withdrew their slate and will not vote proxies; the parties agreed to identify and appoint a New Director to the Board within 60 to 90 days from the conclusion of the 2026 Annual Meeting, with that director joining the Nominating and Governance Committee until the 2027 Annual Meeting. The Board also agreed to form two new committees and adopt director ownership and resignation policies in Q3 of fiscal 2026, and company management will meet quarterly with the Concerned Vaxart Stockholders following quarterly earnings.
Vaxart, Inc. entered into a Cooperation Agreement with a stockholder group that resolves a proxy contest ahead of the 2026 Annual Meeting of Stockholders. The stockholder group has withdrawn its competing director nominations and its demand to inspect certain company books and records.
Vaxart and the group will work together in the 60- to 90-day period after the 2026 meeting to select a mutually agreed independent “New Director,” who will join the Board and the Nominating and Corporate Governance Committee and chair a new Stockholder Engagement Committee. The Board will also form a Clinical and Regulatory Affairs Committee, adopt director resignation and stock ownership policies, and refresh key committee leadership.
Management will meet with the stockholder group at least once per fiscal quarter to discuss financial and strategic matters based on public information. Vaxart will reimburse the group’s documented expenses up to $650,000. The agreement includes customary voting, standstill and non-disparagement provisions and runs through a termination date tied to nomination deadlines for the 2027 or potentially 2028 annual meetings.
Vaxart, Inc. entered into a new modification of its BARDA-funded Project NextGen contract, resetting total funding for its Phase 2b oral COVID‑19 pill vaccine trial to approximately $345 million, which is about $116 million lower than the prior modification after trial enrollment was cut roughly in half by a BARDA partial termination.
The revised amount includes about $68 million of firm fixed price funding, with the remainder reimbursing trial preparation and execution costs, and also releases roughly $29 million to complete the study and perform exploratory safety and efficacy analyses. Vaxart expects to report 12‑month data from a 400‑participant sentinel cohort in the coming weeks and from the 5,085‑participant main cohort in the first half of 2027.
Vaxart, Inc. faces a shareholder-led proxy contest: a coalition calling itself the Concerned Vaxart Stockholders, owning 1,515,343 shares, filed a definitive proxy statement and universal proxy card seeking to elect three nominees to the Board at the 2026 annual meeting.
The group asks for greater transparency, accountability, and Board-level reforms including a Clinical and Regulatory Affairs Committee and a Stockholder Relations Committee, and outlines strategic partnership ideas while emphasizing constructive engagement rather than disruption.
Concerned Vaxart Stockholders, a retail coalition holding 1,515,343 shares, filed a definitive proxy and a GOLD universal proxy card to elect three nominees — Daniel P. Houle, Mark Silverberg, DDS, MD, and Matthew M. Wallace, MD — to Vaxart’s board at the July 16, 2026 annual meeting. The group cites a 91% decline in the share price, approximately $343 million in cumulative losses since 2020, executive compensation of $5.2 million for fiscal 2025, issuance of 50 million new shares on June 13, 2024, and prior governance disputes including a rejected reverse stock split vote and disclosure concerns regarding a former director.
Vaxart, Inc. is soliciting proxies for its 2026 virtual Annual Meeting and is asking stockholders to vote FOR its six director nominees on the enclosed WHITE proxy card. The Board states that a stockholder, Daniel P. Houle, intends to nominate three opposing candidates and urges holders to discard any [•] proxy cards received from Mr. Houle.
The filing recounts prior engagement with Mr. Houle and other stockholders dating to August 2025, describes the Board’s candidate selection and recent appointment of James B. Breitmeyer, M.D., Ph.D., and summarizes prior governance actions including two reverse-split proposals in 2025, Nasdaq delisting actions, and related shareholder solicitations.